Indication

Heterozygous familial hypercholesterolemia

Heterozygous familial hypercholesterolemia is an inherited genetic metabolic disorder of lipid metabolism characterized by life-long, severely elevated circulating levels of low-density lipoprotein cholesterol. Read more about Heterozygous familial hypercholesterolemia

274 drugs 112 manufacturers

Advertisement

Drugs that treat it

Common Heterozygous familial hypercholesterolemia therapies.

Showing 217–225 of 274 drugs

PRAVASTATIN SODIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
DENTON PHARMA I

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
DENTON PHARMA I

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
APHENA PHARMA S

LOVASTATIN

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+7
APHENA PHARMA S

PRAVASTATIN SODIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
APHENA PHARMA S

ROSUVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
APHENA PHARMA S

SIMVASTATIN

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+13
APHENA PHARMA S

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
NOVADOZ PHARMAC

ATORVASTATIN CALCIUM

ANTIHYPERLIPIDEMICS HMGCO-A REDUCTASE INHIBITORS (STATINS)·HYPERCHOLESTEROLEMIA·+11
NIVAGEN PHARMAC
Filter & compare in the drug finder →Opens the drug finder with Heterozygous familial hypercholesterolemia preselected.

News & literature

Coming soon

Related codes

Coming soon
Coming soon

About Heterozygous familial hypercholesterolemia.

Heterozygous familial hypercholesterolemia is an inherited genetic metabolic disorder of lipid metabolism characterized by life-long, severely elevated circulating levels of low-density lipoprotein cholesterol.

Caused by a single pathogenic variant inherited from one parent—most commonly in the low-density lipoprotein receptor (*LDLR*), apolipoprotein B (*APOB*), or *PCSK9* genes—the condition impairs normal hepatic low-density lipoprotein clearance.

This chronic lipid accumulation affects the vascular and integumentary systems, significantly accelerating systemic atherosclerosis and predisposing affected individuals to premature coronary artery disease, early myocardial infarction, and extravascular deposits such as tendon xanthomas and corneal arcus.

Personalize your experience

Follow Heterozygous familial hypercholesterolemia and get updates as they land.

Create a free account

Follow an indication and get alerts when its drugs, labels, or guidelines change

Save any drug on this page to your favorites, synced across devices

AI-curated peer-reviewed research, summarized for your specialty

A morning digest of indication-relevant updates, when you want it